Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells

LING WANG1,2, XIANGLU LI1, XINYU LIU1, KANG LU1, NA CHEN1, PEIPEI LI1, XIAO LV1 and XIN WANG1,3

1Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021; 2Department of Hematology, Taian City Central Hospital, Tai'an, Shandong 271000; 3Institute of Diagnostics, Shandong University, Jinan, Shandong 250012, P.R. China

Received May 7, 2014; Accepted January 16, 2015

DOI: 10.3892/ol.2015.2941

Abstract. The aim of the present study was to investigate the indirubin-enhanced effects of arsenic disulfide (As2S2) on the proliferation and apoptosis of diffuse large B-cell lymphoma (DLBCL) cells in order to identify an optimum combination therapy. The human DLBCL cells, LY1 and LY8, were treated with different concentrations of indirubin for 24, 48 and 72 h. Next, the cells were treated with 10 μM As2S2, or a combination of 10 μM As2S2 and 20 μM indirubin for 48 h. Cell proliferation inhibition was detected using cell counting kit-8 and cell apoptosis was determined using flow cytometry. The expression levels of Bcl-2, Bcl-2-associated X protein (Bax) and caspase-3 were analyzed by quantitative polymerase chain reaction (qPCR) and western blotting. The DLBCL cell viability exhibited no significant changes at 24, 48 or 72 h with increasing indirubin concentration. In addition, the apoptotic rates of the LY1 and LY8 cells demonstrated no noticeable effects at 48 h with increasing indirubin concentration. Following treatment with the combination of indirubin and As2S2, the inhibitory and apoptotic rates of the cells were notably increased compared with those of the As2S2-treated group. The qPCR results revealed that indirubin alone had no enhancing effect upon the Bax/Bcl-2 mRNA expression ratio and caspase-3 mRNA expression. Western blot analysis revealed that indirubin alone had an enhancing effect upon the Bax/Bcl-2 protein ratio and procaspase-3 protein expression. In addition, the results demonstrated that the 21-KDa Bax protein was proteolytically cleaved into an 18-KDa Bax in the DLBCL cells treated with the combination of indirubin and As2S2. Indirubin alone did not inhibit proliferation or induce the apoptosis of the LY1 and LY8 cells. However, the combination of indirubin and As2S2 yielded enhancing effects. Therefore, the results of the present study demonstrated that with regard to antitumor activities, As2S2 served as the principal drug, whereas indirubin served as the adjuvant drug. The enhancing effect was due, in part, to the induction of the mitochondrial apoptotic pathway, which involves the cleavage of Bax.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most frequently diagnosed lymphoid tumor, accounting for 40% of all non-Hodgkin lymphomas (NHLs) among adults in Western countries (1). DLBCL is also common in developing countries (2,3). Although traditional chemical therapies and bone marrow transplantations can increase survival rates and even cure certain patients (4), relapse and drug resistance remain a clinical challenge (5).

In order to enhance therapeutic efficacies and reduce adverse effects, multiple drugs are often combined to treat diseases (6). Prescriptions, termed formulae, have been widely used in traditional Chinese medicine (TCM). In general, formulae are composed of several components, including a primary ingredient and additional adjunctive ones. Realgar has demonstrated good anti-tumor effects as part of a Realgar-Indigo naturalis formula (RIF); this combines realgar with indigo naturalis, Radix Salvia miltiorrhiza and Radix Pseudostellariae heterophylla. RIF has previously demonstrated effectiveness in the treatment of acute promyelocytic leukemia (APL) (7-10). Further research has indicated that arsenic disulfide (As2S2) or tetra-arsenic tetra-sulfide (As4S4) and indirubin, components of realgar and indigo naturals, are the primary functioning ingredients of RIF (10).

As2S2 has been used in Western medicine and TCM for several hundred years. Previous studies have demonstrated that realgar is able to induce the apoptosis of a variety of malignant hematological cells (7,10-20). It has also been established that As2S2 is able to trigger the degradation of the PML-RARα oncoprotein, and indirubin-augmented As2S2-triggered catabolism of the PML-RARα oncoprotein (10). The findings of our previous study demonstrated that As2S2 induced the apoptosis of DLBCL cells (21). However, it is yet to be elucidated whether indirubin alone or in combination with As2S2 exhibits the most significant effects in DLBCL cells. The present study aimed to investigate the indirubin-enhanced effects of As2S2 on the...
proliferation and apoptosis of DLBCL cells, and to determine its underlying mechanism in order to identify an optimum combination therapy for the treatment of DLBCL.

Materials and methods

Cell lines and cell culture. The LY1 and LY8 cell lines (Albert Einstein College of Medicine, Bronx, NY, USA) were maintained as a suspension at 37°C in 5% carbon dioxide in a humidified atmosphere. The cells were cultured in Iscove's modified Dulbecco's medium (IMDM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone). Cells in the exponential growth phase were then seeded into 96-well plates or culture flasks.

Antibodies and reagents. Indirubin (95% in purity) was purchased from Aladdin Reagents Co., Ltd. (Shanghai, China). The indirubin was first dissolved in dimethyl sulfoxide to generate a 20-M stock solution. Next, the stock solution was passed through a 0.22-µm filter. The aliquots were further diluted in IMDM supplemented with 10% FBS prior to each experiment in order to prepare the working solutions. The monoclonal rabbit anti-human B-cell lymphoma 2 (Bel-2; 1:1,000), rabbit anti-human Bcl-2-associated X protein (Bax; 1:1,000) and rabbit anti-human caspase-3 (1:1,000) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The polyclonal mouse anti-human β-actin (1:1,000) antibody was obtained from the Zhongshan Goldenbridge Biotechnology Co., Ltd. (Beijing, China).

Assessment of cellular cytotoxicity using the cell counting kit-8 (CCK-8). Cell proliferation was analyzed using the CCK-8 assay (Beyotime Institute of Biotechnology, Haimen, China). In total, 1x10⁴ cells/100 µl/well of the LY1 and LY8 cells were seeded into 96-well plates, treated with various concentrations of indirubin (1, 5, 10, 15 and 20 µM), and then cultured for 48, and 72 h in a humified atmosphere in a 5% carbon dioxide incubator. Next, the cells were treated with 10 µM As₂S₃ (99.53% purity, Alfa Aesar Company, Shanghai, China) and 20 µM indirubin, alone or in combination, for 48 h. Each experiment was performed in triplicate. The cells were then incubated with 10 µl CCK-8 at 37°C for 4 h. An ELISA reader (Spectra Max M2; Molecular Devices LLC, Sunnyvale, CA, USA) was then used to measure the optical density of each well at 450 nm.

Assessment of apoptosis using Annexin V and propidium iodide (PI). The apoptotic rate of the LY1 and LY8 cells was analyzed using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (KeyGen Biotech Co., Ltd., Nanjing, China). First, the cells were treated with different concentrations of indirubin and As₂S₃, alone or in combination, for 48 h. Dual staining with Annexin V-FITC and PI was then performed according to the manufacturer’s instructions. In total, 5-10x10⁵ cells were analyzed using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). FlowJo 7.6 software (FlowJo LLC, Ashland, OR, USA) was then used to process the data. The cells that were negative for the Annexin V-FITC and PI stain were identified as viable cells. The cells that were positive for Annexin V-FITC, but negative for PI were considered to be early apoptotic cells, while those with positive Annexin V-FITC and PI staining were identified to be late apoptotic cells. The sum of the early and late apoptotic cells constituted the total number of apoptotic cells.

Gene expression study using quantitative polymerase chain reaction (qPCR). The total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) from the DLBCL cells that had been treated with indirubin and As₂S₃, alone or in combination, and from the untreated cells. The reverse transcription reaction step was then performed using Takara reverse transcription reagents (Takara, Dalian, China). The amplification reactions were performed using SYBR Premix Ex Taq (Takara) on a Roche LightCycler 480 Real-Time PCR System (Roche Diagnostics, Basel, Switzerland). Specific primers for the qPCR were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). The primer sequences are listed in Table 1. In order to control the variability in expression levels, the data were normalized to the geometric mean of the housekeeping gene, β-actin. For the data analysis, the 2-ΔΔCt method was used. The qPCR for each gene of each cDNA sample was performed in triplicate.

\[ \Delta Ct = Ct (\text{target gene}) - Ct (\beta-\text{actin gene}) \]

\[ \Delta \Delta Ct = \Delta Ct (\text{drug-treated cells}) - \Delta Ct (\text{untreated control}) \]

Protein expression analysis using western blotting. SDS-PAGE and western blot analysis were performed in order to evaluate the protein levels of Bax, Bel-2 and caspase-3. The total protein was extracted from the DLBCL cells treated with indirubin and As₂S₃, alone or in combination, and from the untreated cells, using a radioimmunoprecipitation assay and 1% phenylmethylsulfonyl fluoride (Shenergy Biocolor Bioscience and Technology Co., Ltd., Shanghai, China). Next, the bicinchoninic acid assay (Shenergy Biocolor Bioscience and Technology Co., Ltd.) was used to determine the protein concentration of the samples. The proteins were detected using a chemiluminescence detection kit (EMD Millipore, Billerica, MA, USA). The results of the western blot analysis were analyzed using ImageQuant Las 4000 software (GE Healthcare Life Sciences, Shanghai, China) and Multi Gauge version 3.0 software (Fujifilm Life Science, Tokyo, Japan).

Statistical analysis. Statistical analysis was performed using SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). The data are presented as the mean ± standard deviation. An analysis of variance was used to evaluate the data from the cellular viability and apoptosis assays. Additional statistical analyses were performed using Student’s t-test. P<0.05 was used to indicate a statistically significant difference.

Results

Effects of indirubin and As₂S₃, alone or in combination, on the viability of DLBCL cells. The effect of indirubin and As₂S₃, alone or in combination, on the viability of the LY1 and LY8 cells was investigated. The results demonstrated that there was no significant effect on the viability of the cells following incubation with different doses of indirubin (1, 5, 10, 15 and 20 µM) for different lengths of time (24, 48 and
72 h) (Fig. 1). Compared with the untreated control group, treatment with 10 µM As$_2$S$_2$ for 48 h resulted in a cell viability of 21.30±2.10% and 13.89±0.46% for the LY1 and LY8 cells, respectively (P<0.01). The inhibitory effect on cell viability was enhanced following treatment with the combination of 10 µM As$_2$S$_2$ and 20 µM indirubin. The cell viability rate in the combination group was 10.56±1.27 and 8.20±1.70% for the LY1 and LY8 cells, respectively (P<0.01).

Significant differences were identified between the cell viability rate of the As$_2$S$_2$-treated group and the combination-treated group (P<0.01).

**Effects of indirubin and As$_2$S$_2$, alone or in combination, on the transcription levels of Bax, Bcl-2 and caspase-3 genes in DLBCL cells.** Our previous study demonstrated that As$_2$S$_2$-induced apoptosis was dependent upon the mitochondrial-mediated apoptosis pathway (21). In order to investigate whether the combination treatment led to enhancement of the mRNA levels of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed. As shown in Fig. 4, no significant differences in the expression of the Bax, Bcl-2 and caspase-3 genes, qPCR was performed.
Figure 2. Effects of indirubin and arsenic disulfide (As$_2$S$_2$), alone or in combination, on the apoptosis of LY1 cells. LY1 cells were incubated with different doses of indirubin (1, 5, 10, 15 and 20 µM) and also 10 µM As$_2$S$_2$ and 20 µM indirubin, alone or in combination, for 48 h. (A) The apoptotic rate was determined using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) dual staining followed by flow cytometric analysis. The lower left quadrant (Q4) indicates the percentage of viable cells (Annexin V-FITC- and PI-negative), the upper left quadrant (Q1) indicates the percentage of early apoptotic cells (Annexin V-FITC-positive and PI-negative) and the upper right quadrant (Q2) indicates the percentage of late apoptotic cells (Annexin V-FITC- and PI-positive). (B) There were no significant effects on the rate of apoptosis of the LY1 cells following incubation with different doses of indirubin. However, significant differences were evident between the As$_2$S$_2$-treated group and the combination-treated group. Values are expressed as the mean ± standard deviation. *$P<0.01$ vs. untreated control. DMSO, dimethyl sulfoxide.

Figure 3. Effects of indirubin and arsenic disulfide (As$_2$S$_2$), alone or in combination, on the apoptosis of LY8 cells. LY8 cells were incubated with different doses of indirubin (1, 5, 10, 15 and 20 µM) and also 10 µM As$_2$S$_2$ and 20 µM indirubin, alone or in combination, for 48 h. (A) The apoptotic rate was determined using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) dual staining followed by flow cytometric analysis. The lower left quadrant (Q4) indicates the percentage of viable cells (Annexin V-FITC- and PI-negative), the upper left quadrant (Q1) indicates the percentage of early apoptotic cells (Annexin V-FITC-positive and PI-negative) and the upper right quadrant (Q2) indicates the percentage of late apoptotic cells (Annexin V-FITC- and PI-positive). (B) There were no significant effects on the rate of cell apoptosis of the LY8 cells following incubation with different doses of indirubin. However, significant differences were evident between the As$_2$S$_2$-treated group and the combination-treated group. Values are expressed as the mean ± standard deviation. *$P<0.01$ vs. untreated control. DMSO, dimethyl sulfoxide.
caspase-3 were investigated. The protein levels following treatment are shown in Fig. 5. Subsequent to treatment for 48 h, the expression of Bcl-2 was markedly downregulated, whereas the expression of Bax was notably upregulated in the LY1 and LY8 cells of the combination group compared with the control. Furthermore, the Bax/Bcl-2 ratio was significantly increased.

Our previous study demonstrated that following exposure to 10 µM As₂S₂, the levels of the 21-KDa Bax protein and the 18-KDa Bax cleavage protein were markedly increased (21). Western blot analysis also revealed that following treatment, the levels of the 21-KDa Bax protein and the cleaved 18-KDa Bax protein were elevated in the combination group. By contrast, procaspase-3 expression was evidently reduced.

Discussion

Previous studies have demonstrated that indirubin and its derivatives inhibit the proliferation and induce the apoptosis of a number of malignant cells (22-50). Previous studies have also demonstrated that indirubin derivatives induce G₂/M arrest by inhibiting cyclin-dependent kinases and inducing apoptosis via the mitochondria-dependent pathway (49,51,52). In human malignant B (IM9 and Reh6) and T (Jurkat and CEM-T) cells, indirubin-3-oxime and 6-bromo-indirubin-3-monoxime were shown to initiate cell cycle inhibition and apoptosis. In the same way, meisoindigo inhibited the proliferation and induced the apoptosis of Jurkat cells in a dose-dependent manner. In addition to the onset of apoptosis, caspases 2, 3, 8 and 9 were activated and AKT phosphorylation was decreased in Jurkat cells following meisoindigo treatment. A study by Kim et al revealed that the indirubin derivative, 5-fluoro-indirubin, had a synergic effect on 1,25-dihydroxyvitamin D₃ (1,25-(OH)₂D₃)- and all-trans retinoic acid-induced differentiation HL-60 leukemia cells (53).

In a previous study, indirubin derivatives demonstrated biphasic effects in prostate cells. The derivatives stimulated
the growth of androgen-dependent prostate cancer cells at sub-apoptotic concentrations, but also inhibited the proliferation and induced the apoptosis of prostate cancer cells at higher concentrations, causing cell toxicity and apoptosis (54). The results of the present study revealed that indirubin alone had no effect upon the proliferation and apoptosis of the DLBCL cells. However, when combined with As$_{S_2}$, indirubin had an enhancing effect upon the proliferation and apoptosis of the cells, which was consistent with the findings of previous studies. Wang et al revealed that indirubin alone had no effect on the differentiation of APL cells, but that it could enhance As$_{S_2}$-induced differentiation. Furthermore, although indirubin did not cause degradation of the PML-retinoic acid receptor $\alpha$ (PML/RAR$\alpha$) oncoprotein, it enhanced the As$_{S_2}$-triggered degradation of PML/RAR$\alpha$ and initiated ubiquitination (10). Therefore, indirubin served as an adjuvant ingredient for the treatment of APL.

It is well known that apoptosis is key to the development and maintenance of homeostasis in multiple organisms. The results of our previous study suggested that As$_{S_2}$ inhibited the proliferation and induced the apoptosis of DLBCL cells in vitro via the mitochondrial pathway (21). Bax was revealed to be important for the initiation of apoptosis in the As$_{S_2}$-treated DLBCL cells. The results of the present study demonstrated that the combination of As$_{S_2}$ and indirubin notably enhanced the apoptosis of the DLBCL cells. Such findings should encourage further studies to investigate the value of this TCM formula. Future studies that investigate indirubin derivatives with higher water-solubility are required in order to identify a novel formula with improved antitumor characteristics.

In conclusion, indirubin alone did not inhibit the proliferation or induce the apoptosis of the DLBCL cells. However, the combination of indirubin and As$_{S_2}$ yielded enhancing effects. Therefore, the results of the present study suggested that As$_{S_2}$ served as the principal drug and that indirubin served as the adjuvant drug. The enhancing effect was due, in part, to the induction of the mitochondria-dependent apoptotic pathway, which involves the cleavage of Bax.

Acknowledgements
The authors would like to thank the Central Laboratory of the Provincial Hospital Affiliated to Shandong University for providing aid in the present study. This study was supported by grants from the National Natural Science Foundation (no. 81270598), the Natural Science Foundation of Shandong Province, China (nos. ZR2009CM059 and ZR2012HZ003) and the Project of Scientific and Technological Development of Shandong Province, China (no. 2010GSF10250).

References
1. Nedomova R, Papajik T, Prochazka V, Indrad K and Jarosova M: Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157: 239-247, 2012.
2. Abid MB, Nasim F, Anwar K and Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev 6: 531-534, 2005.
3. Sabattini E, Bacci F, Sagramoso C and Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102: 83-87, 2010.
4. Stefancikova L, Moulis M, Fabian P, et al: Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol 39: 1413-1420, 2011.
5. Al-Ahmedi M, Goepel JF, Horsman JM and Hancock BW: Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre. Int J Oncol 40: 2075-2080, 2012.
6. Ahn JC, Kang JW, Shin JJ and Chung PS: Combination treatment with photodynamic therapy and curcumin induces mitochondria-dependent apoptosis in AMC-HN3 cells. Int J Oncol 41: 2184-2190, 2012.
7. Hu XM, Liu F and Ma R: Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 16: 368-377, 2010.
8. Zhen T and Chen SJ: Progress on targeted therapy of acute myeloid leukemia with active components of Chinese herbal medicines. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 14-18, 2009 (In Chinese).
9. Sun F, Chen NN and Cheng YB: Compound realgar and realgar indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao 6: 639-642, 2008 (In Chinese).
10. Wang L, Zhou GB, Liu P, et al: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105: 4826-4831, 2008.
11. Qi J, Zhang M and He PC: Establishment of two-dimensional electrophoresis proteomic profiles of retinoic acid resistant human acute promyelocytic leukemia NB4-R1 cells with apoptosis induced by realgar. Zhongguo Zhong Xi Yi Jie He Za Zhi 31: 391-396, 2011 (In Chinese).
12. Qi J, Zhang M, He PC, Wang HL and Wang XY: Proteomic study of retinoic acid resistant NB4R1 cells apoptosis induced by realgar. Zhonghua Xue Ye Xue Za Zhi 31: 752-757, 2010 (In Chinese).
13. Wang MC, Liu SX and Liu PB: Gene expression profile of multiple myeloma cell line treated by realgar. J Exp Clin Cancer Res 25: 243-249, 2006.
14. Wang MC, Liu SX and Liu PB: Effect of realgar on the gene expression profile of multiple myeloma cell line RPMI 8226. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31: 24-27, 2006 (In Chinese).
15. Zhang C, Huang SL, Xiang Y and Guo AX: Study on Realgar inducing apoptosis in T lymphocytic cell line CEM. Zhong Xi Yi Jie He Xue Bao 1: 42-43, 2003 (In Chinese).
16. Zhao XA and Liu SX: Effects of realgar on tissue factor expression of NB4 and MR2 cells. Zhongguo Zhong Yao Za Zhi 28: 553-556, 2003 (In Chinese).
17. Wang H, Liu S, Lu X, Zhao X, Chen S and Li X: Gene expression profile changes in NB4 cells induced by realgar. Chin Med J (Engl) 116: 1074-1077, 2003.
18. Wang HY and Liu SX: Investigation on NB4 cell responses to realgar by cDNA microarray. Zhongguo Zhong Yao Za Zhi 27: 600-604, 2002 (In Chinese).
19. Li JE, Wu WL, Wang ZY and Sun GL: Apoptotic effect of As2S2 on K562 cells and its mechanism. Acta Pharmacol Sin 23: 991-996, 2002.
20. Shen S, Fang Y, Ma L, Liu S and Li X: Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. Int J Oncol 40: 1089-1096, 2012.
21. Wang L, Liu X, Li X, et al: Arsenic disulfide induces apoptosis of human diffuse large B cell lymphoma cells involving Bax and caspase-3. Oncol Rep 30: 2427-2434, 2013.
22. Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH and Ahn SG: Inhibition of Plk1 and Pin1 by 5′-nitro-indirubinoxime suppresses human lung cancer cells. Cancer Lett 316: 97-104, 2012.
23. Kim SH, Choi SJ, Kim YC and Kuh HJ: Anti-tumor activity of noble indirubin derivatives in solid human tumor models in vitro. Arch Pharm Res 32: 915-922, 2009.
24. Kunz M, Driller KM, Hein M, et al: Synthesis of thia-analogous indirubin N-Glycosides and their influence on melanoma cell growth and apoptosis. ChemMedChem 5: 534-539, 2010.
25. Libnow S, Methling K, Hein M, et al: Synthesis of indirubin-N'-glycosides and their anti-proliferative activity against human cancer cell lines. Bioorg Med Chem 16: 5570-5583, 2008.
26. Naran S, Buettner R, Turkson J, et al: Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102: 5998-6003, 2005.
Inhibitory effects of 5'-OH-5'-nitro-Indirubin Indirubin derivatives induce 5'-Nitro-indirubinoxime, an indirubin derivative, suppresses apoptotic pathways by bromo-substituted indirubin derivatives in melanoma cells associated with inhibition of STAT3 and Akt activation. Biochim Biophys Acta 1800: 352-358, 2011.

31. Suzuki K, Adachi R, Hirayama A, et al: Indirubin, a Chinese anti-leukaemia drug, promotes neoplastic differentiation of human myelocytic leukaemia HL-60 cells. Br J Haematol 130: 681-690, 2005.

32. Lee MY, Liu YW, Chen MH, et al: Indirubin-3'-monoxime promotes autophagic and apoptotic death in JIM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells. Oncol Rep 29: 2072-2078, 2013.

33. Kim WS, Lee MJ, Kim DH, et al: 5'-OH-5'-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells. Leuk Res 37: 427-433, 2013.

34. Liao XM and Leung KN: Indirubin-3'-oxide induces mitochondrial dysfunction and triggers growth inhibition and cell cycle arrest in human neuroblastoma cells. Oncol Rep 29: 371-379, 2013.

35. Shi RZ, Hu XL and Peng HW: The cytotoxicity of indirubin derivative PHI-7 against human breast cancer MCF-7/ADR cells and its mechanisms. Zhongguo Zhong Xi Yi Jie He Za Zhi 32: 1521-1525, 2012 (In Chinese).

36. Nam S, Chen MH, Schroeder A, et al: Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 7: 369-378, 2013.

37. Liu L, Kritsandi M, Magiatis P, et al: A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther 13: 1255-1261, 2012.

38. Nicolaou KA, Liapis V, Evdokiou A, et al: Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells. Biochem Biophys Res Commun 429: 76-82, 2012.

39. Nam S, Scuto A, Yang F, et al: Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat3 signaling. Mol Oncol 6: 276-283, 2012.

40. Kim SA, Kwon SM, Kim JA, Kang KW, Yoon JH and Ahn SG: 5'-Nitro-indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin BI/FAK/Akt signaling. Cancer Lett 306: 197-204, 2011.

41. Berger A, Quast SA, Plotz M, et al: Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative - Enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol 81: 71-81, 2011.

42. Perabo FG, Landwehrs G, Frössler C, Schmidt DH and Mueller SC: Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells. Urol Oncol 29: 815-820, 2011.

43. Choo SJ, Lee JE, Jeong SY, et al: 5'-substituted-indirubin-3'-oxide derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 53: 3696-3706, 2010.

44. Cuong NM, Tai BH, Hoan DH, et al: Inhibitory effects of indirubin derivatives on the growth of HL-60 leukemia cells. Nat Prod Commun 5: 103-106, 2010.

45. Choi SJ, Moon MJ, Lee SD, Choi SU, Han SY and Kim YC: Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett 20: 2033-2037, 2010.

46. Yoon JH, Kim SA, Kwon SM, et al: 5'-Nitro-indirubinoxime induces G1 cell cycle arrest and apoptosis in salivary gland adenocarcinoma cells through the inhibition of Notch-1 signaling. Biochim Biophys Acta 1800: 352-358, 2010.

47. Yoon JH, Kim SA, Kim JI, Park JH, Ahn SG and Yoon JH: Inhibition of invasion and migration of salivary gland adenocarcinoma cells by 5'-nitro-indirubinoxime (5'-NIO). Head Neck 32: 619-625, 2010.

48. Chebel A, Kagiali-Girard S, Catallo R, et al: Indirubin derivatives inhibit malignant lymphoid cell proliferation. Leuk Lymphoma 50: 2049-2060, 2009.

49. Kim SA, Kim SW, Chang S, Yoon JH and Ahn SG: 5'-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett 274: 72-77, 2009.

50. Kameswaran TR and Ramanibai R: Indirubin-3'-monoxide induced cell cycle arrest and apoptosis in Hep-2 human laryngeal carcinoma cells. Biomed Pharmacother 63: 146-154, 2009.

51. Moon MJ, Lee SK, Lee JW, et al: Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg Med Chem 14: 237-246, 2006.

52. Lee JW, Moon MJ, Min HY, et al: Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett 15: 3948-3952, 2005.

53. Kim SH, Kim SW, Choi SJ, Kim YC and Kim TS: Enhancing effect of indirubin derivatives on 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells. Bioorg Med Chem 14: 6752-6758, 2006.

54. Rivest P, Renaud M and Sanderson JT: Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact 189: 177-185, 2011.